Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Innate Pharma S.A. - American Depositary Shares (NQ:IPHA)

2.080 -0.030 (-1.42%)
Streaming Delayed Price Updated: 3:52 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Innate Pharma S.A. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Number of Shares and Voting Rights of Innate Pharma as of May 1, 2022
From Innate Pharma SA
Via Business Wire
Innate Pharma Establishes an At-The-Market (“ATM”) Program on Nasdaq
From Innate Pharma SA
Via Business Wire
Innate Pharma Announces Conference Call and Webcast for Q1 2022 Business Update
From Innate Pharma SA
Via Business Wire
The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
70 Biggest Movers From Friday
Gainers GTY Technology Holdings Inc. (NASDAQ: GTYH) shares climbed 115.2% to close at $6.09 as the company agreed to be acquired by GI Partners. Vaxxinity, Inc. (NASDAQ: VAXX)... 
Via Benzinga
28 Stocks Moving in Friday's Pre-Market Session
Gainers Zymeworks Inc. (NASDAQ: ZYME) rose 40.3% to $6.97 in pre-market trading. Zymeworks 13D filing confirmed earlier reporting of offer letter from Blue Falcons for $10.50 per... 
Via Benzinga
48 Stocks Moving In Friday's Mid-Day Session
Gainers Belite Bio Inc. ADR (NASDAQ: BLTE) shares surged 144.8% to $14.69. Belite Bio priced its 6 million ADS IPO at $6 per ADS. GTY Technology Holdings Inc. (NASDAQ:... 
Via Benzinga
Innate Pharma: First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial Triggers $50M Payment From AstraZeneca
From Innate Pharma SA
Via Business Wire
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 20, 2022
From Innate Pharma SA
Via Business Wire
Innate Pharma Files Its 2021 Universal Registration Document (Document d’enregistrement universel) and 2021 Annual Report on Form 20-F
From Innate Pharma SA
Via Business Wire
Earnings Scheduled For March 24, 2022
Companies Reporting Before The Bell • iHuman (NYSE:IH) is likely to report earnings for its fourth quarter. • Pioneer Muni High Inc (NYSE:MAV) is expected to... 
Via Benzinga
Innate Pharma Reports Full Year 2021 Financial Results and Business Update
From Innate Pharma SA
Via Business Wire
Innate Pharma FY 2021 Earnings Conference Call On March 24, 2022 At 09:00 AM ET
Innate Pharma (NASDAQ:IPHA) will host a conference call at 09:00 AM ET on March 24, 2022, to discuss FY 2021 earnings results. How to Attend Innate Pharma (IPHA) Conference Call... 
Via Benzinga
Innate Pharma Announces Conference Call and Webcast for Full Year 2021 Financial Results
From Innate Pharma SA
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Innate Pharma (NASDAQ:IPHA) stock increased by 13.7% to $3.32 during Thursday's pre-market session. The market value of their outstanding shares is at $264.6... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers 
Via Benzinga
Number of Shares and Voting Rights of Innate Pharma as of February 1, 2022
From Innate Pharma SA
Via Business Wire
Innate Pharma to Participate in Upcoming Investor Conferences
From Innate Pharma SA
Via Business Wire
20 Stocks Moving in Tuesday's Pre-Market Session
Gainers Aptorum Group Limited (NASDAQ: APM) shares rose 94.4% to $3.15 in pre-market trading after gaining around 10% on Monday. The FDA recently granted Orphan Drug Designation... 
Via Benzinga
Number of Shares and Voting Rights of Innate Pharma as of January 1, 2022
From Innate Pharma S.A.
Via Business Wire
The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Annexon Announces Mixed Phase 2 Data From Huntington Disease Trial Annexon,... 
Via Benzinga
Innate Pharma Obtains €28.7m in Non-Dilutive Financing in the Form of State Guaranteed Loans
From Innate Pharma SA
Via Business Wire
Innate Pharma to Participate in Upcoming Investor Conferences
From Innate Pharma SA
Via Business Wire
18 Stocks Moving in Monday's Pre-Market Session
Gainers Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) rose 41.6% to $3.13 in pre-market trading after gaining around 8% on Friday. Armstrong Flooring, Inc. (NYSE: AFI... 
Via Benzinga
Innate Pharma: First Patient Dosed in IPH6101/SAR443579 Phase 1/2 Clinical Trial in Various Blood Cancers
From Innate Pharma SA
Via Business Wire
Innate Pharma Says Chemo-Free Monalizumab Triplet Therapy Shows Preliminary Anti-Cancer Activity
Innate Pharma SA's (NASDAQ: IPHA) data from the Phase 2 expansion cohort (cohort 3) evaluating the monalizumab triplet combination shows preliminary activity and an... 
Via Benzinga
The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Committee Votes Against Recommending Approval Of Kidney Disease Drug... 
Via Benzinga
Exposures COVID-19 Product Safety
Innate Pharma: Monalizumab Combined With Cetuximab and Durvalumab Demonstrates Anti-Tumor Activity in First-Line Recurrent or Metastatic Head and Neck Cancer at ESMO Immuno-Oncology 2021 Congress
From Innate Pharma S.A.
Via Business Wire
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
Exposures Product Safety
Innate Pharma to Present Monalizumab Data at ESMO Immuno-Oncology 2021 Congress
From Innate Pharma SA
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.